Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis

The development of tumor lysis syndrome (TLS) in association with treatment for myeloproliferative neoplasms (MPNs) is relatively rare. We herein present the case of a post-polycythemia vera (PV) myelofibrosis patient with massive splenomegaly who developed laboratory TLS after treatment with ruxoli...

Descripción completa

Detalles Bibliográficos
Autores principales: Koshiishi, Megumi, Sueki, Yuki, Kawashima, Ichiro, Nakajima, Kei, Mitsumori, Toru, Kirito, Keita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635310/
https://www.ncbi.nlm.nih.gov/pubmed/28794380
http://dx.doi.org/10.2169/internalmedicine.8706-16
_version_ 1783270260616462336
author Koshiishi, Megumi
Sueki, Yuki
Kawashima, Ichiro
Nakajima, Kei
Mitsumori, Toru
Kirito, Keita
author_facet Koshiishi, Megumi
Sueki, Yuki
Kawashima, Ichiro
Nakajima, Kei
Mitsumori, Toru
Kirito, Keita
author_sort Koshiishi, Megumi
collection PubMed
description The development of tumor lysis syndrome (TLS) in association with treatment for myeloproliferative neoplasms (MPNs) is relatively rare. We herein present the case of a post-polycythemia vera (PV) myelofibrosis patient with massive splenomegaly who developed laboratory TLS after treatment with ruxolitinib, a potent JAK1/JAK2 inhibitor. She also exhibited a rapid reduction of spleen volume. Our present case suggests the potential risk of TLS development after ruxolitinib treatment, particularly in patients with massive splenomegaly.
format Online
Article
Text
id pubmed-5635310
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-56353102017-10-12 Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis Koshiishi, Megumi Sueki, Yuki Kawashima, Ichiro Nakajima, Kei Mitsumori, Toru Kirito, Keita Intern Med Case Report The development of tumor lysis syndrome (TLS) in association with treatment for myeloproliferative neoplasms (MPNs) is relatively rare. We herein present the case of a post-polycythemia vera (PV) myelofibrosis patient with massive splenomegaly who developed laboratory TLS after treatment with ruxolitinib, a potent JAK1/JAK2 inhibitor. She also exhibited a rapid reduction of spleen volume. Our present case suggests the potential risk of TLS development after ruxolitinib treatment, particularly in patients with massive splenomegaly. The Japanese Society of Internal Medicine 2017-08-10 2017-09-01 /pmc/articles/PMC5635310/ /pubmed/28794380 http://dx.doi.org/10.2169/internalmedicine.8706-16 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Koshiishi, Megumi
Sueki, Yuki
Kawashima, Ichiro
Nakajima, Kei
Mitsumori, Toru
Kirito, Keita
Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
title Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
title_full Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
title_fullStr Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
title_full_unstemmed Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
title_short Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
title_sort tumor lysis syndrome after the administration of ruxolitinib in a patient with post-polycythemia vera myelofibrosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635310/
https://www.ncbi.nlm.nih.gov/pubmed/28794380
http://dx.doi.org/10.2169/internalmedicine.8706-16
work_keys_str_mv AT koshiishimegumi tumorlysissyndromeaftertheadministrationofruxolitinibinapatientwithpostpolycythemiaveramyelofibrosis
AT suekiyuki tumorlysissyndromeaftertheadministrationofruxolitinibinapatientwithpostpolycythemiaveramyelofibrosis
AT kawashimaichiro tumorlysissyndromeaftertheadministrationofruxolitinibinapatientwithpostpolycythemiaveramyelofibrosis
AT nakajimakei tumorlysissyndromeaftertheadministrationofruxolitinibinapatientwithpostpolycythemiaveramyelofibrosis
AT mitsumoritoru tumorlysissyndromeaftertheadministrationofruxolitinibinapatientwithpostpolycythemiaveramyelofibrosis
AT kiritokeita tumorlysissyndromeaftertheadministrationofruxolitinibinapatientwithpostpolycythemiaveramyelofibrosis

Ejemplares similares